John H. Johnson

John Johnson is a recognized leader in the pharmaceutical and biotechnology industry with more than 3 decades of experience. In addition to his current role as CEO of Melinta Therapeutics, Mr. Johnson has held executive management roles at leading global corporations, including Johnson & Johnson, Eli Lilly & Company, ImClone Systems, Inc., Dendreon Corporation and Pfizer, Inc. He recently served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of the Biotechnology Industry Organization (BIO). He also served as chairman, president and chief executive officer of Dendreon and as chief executive officer and a member of the board of directors of Savient Pharmaceuticals, Inc. Prior to these roles, Mr. Johnson served as president of Eli Lilly & Company’s Oncology Unit, following the company’s 2008 acquisition of Imclone Systems, where he served as chief executive officer and a member of ImClone’s board of directors. Prior to Imclone, Mr. Johnson served as the company group chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Prior to that role, Mr. Johnson held several executive positions at Johnson & Johnson, ParkStone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp. and Pfizer, Inc. He previously served as chairman of Tranzyme Pharma, Inc., lead independent director at Sucampo Pharmaceuticals and as a member of the board of BioNJ. Mr. Johnson currently serves on the board of Melinta Therapeutics Inc., and he is chairman of Strongbridge Biopharma plc.